Heparan sulfate proteoglycans (HSPGs) are essential components of the glomerular basement mem brane (GBM) carrying a strong anionic charge. A well-characterized extracellular HSPG is perlecan, ubiquitously expressed in basement membranes. A cDNA construct encoding domains I and II of human perlecan was expressed as a fusion protein with glutathione S-transferase. This fusion protein was used to generate monoclonal antibody 95J 10. We compared the staining pattern of 95J10 with that of M215, a previously prepared mAb that recognizes HSPG isolated from human GBM. In kidney cortex, the antiperlecan mAh 95J10 showed a strong staining of the mesangium, Bowman's capsule, the tubular basement membrane, and stained the GBM only slightly. In contrast, M215 predominantly stained the GBM in a linear fashion, lmmunoeleclron microscopy supported these results, showing concentrations of perlecan in some regions of the GBM, whereas the unidentified M215 antigen was homogenously distributed throughout the GBM. In other human tissues, both antibodies also produced a different staining pattern. Furthermore, a polyclonal antiserum recognizing HSPG isolated from the GBM did not recognize per lecan from El IS tumors. These results provide evidence for the presence of another HSPG in the GBM that is immunologically distinct from perlecan, The absence of perlecan splice variants in the kidney suggests that this component is encoded by a different gene than perlecan. Given its marked expression in the GBM, I his component could be a determining factor in the maintenance of selective glomerular permeability.
kidney with heparitinase, which resulted in leakage of anionic tracer proteins [4] , A similar effect was observed when the kid ney was perfused with anti-HS mAbs [5] . Alterations in the HS content of the GBM causing nephrotic syndrome are involved in, for example, minimal change nephropathy, glomerulonephri tis, diabetes mellitus, and Denys-Drash syndrome [6] [7] [8] ,
For biochemical characterization, HSPGs were extracted from isolated glomeruli [9] , from epithelial cell lines [10] , or from the mouse Engelbreth-HoIm-Swarm sarcoma [11 -13] . Ex traction of HSPG from basement membranes is complicated clue to its strong interactions with other components. In addition, their analysis is confused by their smeared appearance on pro tein gels and their sensitivity to proteolysis. The first basement membrane proteoglycan characterized was termed perlecan, with reference to its beads-on-a-string-like appearance in rotary shad owing electron microscopy [14] . It consists of a 467-kDa core protein carrying five functional domains and three HS chains attached in close proximity to its N-terminus [15] [16] [17] , Human perlecan is expressed by a single gene, named HSPG2, located on the short arm of chromosome 1 [18] [19] [20] . Several observa tions have suggested the presence of additional basement mem brane HSPGs: low-density forms (representing perlecan) and high-density forms characterized by relatively small core pro teins [21, 22] . However, it was demonstrated that these high-density proteoglycans are immunologically related to peiiecan, suggesting that they are generated by proteolytic pro cessing [23] .
Previous immunofluorescence studies performed with vari ous polyclonal and monoclonal antibodies yielded inconsistent results, with particular differences in the staining intensity of the GBM [3, 9, 11, 24, 25] . For the generation of mAbs, prokaryotic expression offers a large advantage over proteoglycan extraction from basement membranes, because the risk of co-immunization with contaminating HSPG species is eliminated. Furthermore, recombinant protein expression allows the development of do main-specific antibodies. We have synthesized domains I and II of human perlecan as a bacterial fusion protein and generated monoclonal antibody 95J10. In this study, we compare the ex pression pattern in human tissues for 95J10 and M215, a mAb that was previously raised against isolated human GBM-HSPG [3] , The results provide evidence for the presence of an uniden tified HSPG in the GBM, which appears to be immunologically distinct from perlecan. Construction of the expression vector pGEX4T3-P12a. A prokaryotic expression vector encoding amino acids 24-404 of human perlecan was prepared as follows. Two PCR products were generated from cDNA clone Hpe2 [16] using Vent poly merase for proofreading activity. The primer sets were: 5'-TCA-TCTCCAGCGGCTCTGT-3' (forward PI), 5'-TCATGGGAAC-TGGGGCACTGTGC-3' (reverse PI), 5'~TCATCTCCAGCGG-CTCTGT-3' (forward P2) and 5'-TTACATGCAGCCAAACTC-GTC-3' (reverse P2, this primer introduces an in-frame stop co don immediately behind amino acid 404). The two PCR prod ucts were inserted into the Srfl cloning site of pCR-Script [26, 27] and screened to detect the unique Notl site at the 3'-end of the cDNA fragments. The P2 fragment was then ligated to the PI fragment by use of the Xcml restriction site, introduced into pGEX4T-3 [28] using the Ncol and Notl cloning sites. The fidel ity of amplification and ligation procedures was checked by se quence analysis. The resulting expression vector was named pGEX4T3-P12a.
EXPERIMENTAL PROCEDURES
Expression and purification of recombinant perlecan-(24-404)-peptide. Expression of the recombinant perlecan-(24-404)-peptide was performed as described in [28] , except that the cell pellet was resuspended in 125 ml ice-cold NaG/P* (140 mM NaCl, 2.7 mM KC1, 10 mM Na2HP04, 2 mM KH2P0<, pH 7.5), 1% Triton X-100, 10 mM N-ethylmaleimide, 5 mM EDTA, 10 mM 6-aminohexanoic acid, 5 mM 2-iodoacetamide, 1 mM phenylmethylsulfonyl fluoride and 1 mM benzamidine/ HC1. Cell lysis and affinity purification of the recombinant fu sion protein were performed in the presence of 1% Triton X-100, which was essential for optimal yields. In contrast, the yield could not be improved by other modifications of the procedure such as the use of sarkosyl for solubilization [29] , growth at 30°C [30] or treatment with Mg2 H and ATP prior to affinity chromatography [31] .
Affinity-purified fusion protein was incubated with 1.7 NIH U/ml human thrombin (specific activity approximately 4000 NIH U/mg) and incubated for 60 min at 22°C. To exhaustively remove the thrombin-digested mixture from the glutathione Stransferase (GST) fragment, it was dialysed against NaCl/Pj to remove free glutathione and passed through a glutathione-conju gated Sepharose 4B column (1 ml) at room temperature. The flow-through was concentrated by ultrafiltration against a 10-kDa cutoff membrane to a final concentration of 0.63 mg/ml (determined by the Bradford method with BSA as reference) [32] .
Antibodies. The anli-perlecan mAb 95J10 was prepared as follows. Mice were immunized and boosted with 20 jag purified perlecan-(24-404)-peptide per injection (this preparation was completely devoid of GST). Iiybridoma cell lines were screened by ELISA with an independently isolated batch of recombinant fusion protein. Twelve positive clones were examined in indirect immunofluorescence studies for their capacity to stain human renal basement membranes. A mAb designated 95J 10 was se lected that showed strong glomerular staining. The mAh also reacted in western blot analysis with the fusion protein and with perlecan-(i-404)-peptide expressed by baculovirus-infected in sect cells [33] , which indicated that it also recognizes the antigen in a denatured conformation. No cross-reactivity of mAb 95J'10 with Escherichia coli proteins or GST was observed by ELISA and western blotting. Experimental animal care, cell fusion, and generation of the monoclonal hybridoma cell line 95J10 were performed by Diabor Ltd, Oulu, Finland.
Other antibodies used were R254 (a rat mAb against mouse perlecan; a generous gift of Dr J. van den Bom), M215 (a mouse mAb against the core protein of HSPG isolated from human GBM [3] ), and K42 (a rabbit antiserum recognizing HSPG from the human and murine GBM [9] ).
Immunological methods. SDS/PAGE and im mu nob lot analyses were carried out following standard procedures [30] , All samples were denatured by boiling in the presence of 2-mercaptoethanol prior to loading onto a homogeneous 5% poly acrylamide gel Immunofluorescence and tissue distribution studies were performed with adult human tissue specimens ob tained during autopsy, snap-frozen in liquid nitrogen, and stored at -80°C until use. Cryostat sections of 2 \ .im were attached to glass slides and treated with acetone for 10 min at 4 Q C for fixa tion. mAb M215 or 95J10 was applied as undiluted hybridoma supernatant. After 1 h incubation at 22°C, specimens were sub merged five times in fresh NaCl/Pj for washing. Bound primary antibody was detected by incubating with fluorescein-isothiocyanate-conjugated sheep-anti-mouse immunoglobulins (30 min at 22°C in the dark). After thorough washing with fresh NaCI/P;, the preparations were examined with a Leitz immunofluores cence microscope. For immunoelectron microscopy, kidney cor tex slices were fixed with periodate-lysine and paraformalde hyde, immersed in 2.3 M sucrose for cryoprotection and snapfrozen in liquid nitrogen. Staining of peroxidase-conjugated an tibody complexes was performed following standard protocols [34] and the sections were postfixed in Epon 812. Thin sections were examined with a Jeol 1200 EX electron microscope.
Northern hybridization. A multiple human tissue northern blot (Clontech Laboratories Inc.) was treated according to the supplier's protocol with an antisense probe homologous to exon 3 of perlecan (S'-AAGTCCCCGCTGCCCAGGTCCCCACTG-CCCAGGTCGT-3') [20] . This exon is a prerequisite for the e given on the left dicale ihe fusion protein in lanes 2 and 3 i IT) and (Fig. 2, lane 5) . The staining signal is w eak co m p ared to the G S T fraction (Fig. 2, lane 6 T he ultra struct ura I distribution of H S P G s in the analyzed by ir (Fig. 4) . T he anti-per lee an m A h 95 J 10 stained the G B M along som e fragments of the capillary wall, whereas other regions show ed no staining at all (Fig. 4 A) . In all cases, the staining
it the endothelial side of the basal lam ina w a s . t \ ¿ n t > (F i g . 4 C ). Besides the I oe a I acc u in n I at i on of pe rl ec a n in t h e G B M , an elevated expression was seen in the m esangial matrix (Fi g . 4 A ), M 215, how e ver, prod need a ho m oge no us stain i n g the G B M (Fig. 4 B and D) . T h e cl its" ) n < ' Poly(A)-rieh mRNA isolated from heart ( I), brain (2), placenta (3), lung (4), liver (5), skeletal muscle (6), kidney (7), and pancreas (8) was hy bridized with a perlecan-specific probe and washed stringently. The bot tom panel shows a control hybridization with a /j-actin-specific probe to indicate differences in total mRNA content.
endornysium that surrounds the skeletal muscle fibers, the capil laries, an artery, nerve fibers with a myelin sheath, and perineu rium (bundles are surrounded by connective tissue). In contrast, in Ab M215 s t ai tied o n 1 y t h e c a pi 1 1 ari e s (Fi g. 51) . In c e reb ru m, 95J 10 strongly stains veins in the cerebral cortex, the arteries, and the capillaries. In the same tissue, mAb M215 only stains t h e c a pill ari e s (Fig. 5J ). I n al 1 cases, th e spec i fi c i t y o f t h e stain ing was checked by parallel incubations without the primary an tibody.
The results obtained by immunohistochemistry suggest the occurrence of two different GBM-associated HSPG species. Could the observed differences be based on different epitope accessibilities in vivol To exclude this possibility, preparations of HSPG isolated from the human GBM and from the mouse EHS tumor were analyzed by western blotting (Fig. 6 ). The EHS tumor is known to produce large amounts of perlecan. Using a rabbit polyclonal antiserum (K42) that recognizes both murine and human GBM-HSPG [9] , no staining of EHS-HSPG was deizave identical results (data not r : \ / > r / ; i shown). As a control for the transfer of EHS-HSPG to the blot, an identical treatment with a rat mAb against mouse perlecan resulted in a marked staining of EHS-HSPG, mAb 95J10 could not be used for this purpose, since it is specific lor human per lecan. The specificity of antiserum K42 for GBM-HSPG, with out any cross-reaction with perlecan, confirms that the two Perlecan splice variants occur in brain, placenta and skeletal muscle but not in kidney. Elucidation of the perlecan gene structure showed the theoretical possibility of alternative splicing [ 16. 17, 20] , Interestingly, the occurrence of splice vari ants would result in the expression of perlecan isoforms. We therefore investigated the occurrence of perlecan splice variants by northern blotting (Fig. 7) , The full size messenger RNA (ap proximately 14 kb) was detected in heart, placenta, skeletal mus cle, kidney and pancreas, but was hardly or not at all present in brain, lung, and liver. Interestingly, a smaller size mRNA species was detected in brain (2.5 -2.6 kb), placenta (1.9 kb and 6.4-6.7 kb) and skeletal muscle (3.1 -3.3 kb). The significance of these molecules is not clear. In the kidney, however, we could not distinguish anv splice variants.
As the presence of strongly anionic HSPGs is important to maintain the selective permeability of the GBM, the identifica tion of perlecan as a basementmiemhrane-associated HSPG has provoked many investigators to study perlecan expression levels during nephropathy. We used mAb 95J10, directed against amino acids 22 - ¿decan, to analyze the distribu tion of perlecan in the glomerulus in more detail. The staining pattern of 95J10 in indirect immunofluorescence is in agreement with other studies performed with mAbs raised against recombi nant fragments from domain HI of perlecan [24, 25] , and with a polyclonal antiserum against perlecan from the EHS-tumor [11] . [35) . Another study supported the synthesis of perlecan-like HSPG by cultured rat mesangial cells |36|. Finally, partial amino acid sequences of HSPG isolated from bovine and human kidney also supported the presence of HSPG species that are unrelated to perlecan [37, 381 . After hybridization of kidney m R N A , only the full-length perlecan transcript could be distinguished (Fig. 7) . Although m i 
